Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Recent patents related to the use of optogenetics for neural stimulation, interface for prosthetic devices and control of the secretion of polypeptides of interest.
An empirical study of publicly funded collaborative research projects in biotechnology identifies contractual provisions that govern the extent of access to and openness of research results.
How will today’s patent law affect tomorrow’s innovation in the areas of biomarkers and nature-based products; diagnostics; and algorithms, big data and AI?
Deep patent portfolios help drugmakers block market entry by potential biosimilars, but many biologic patents logically cannot be valid barriers to competitive entry.
US Patent and Trademark Office data show a slowing of NIH-supported cancer patent innovation since 1995, amid criticism of an incremental rather than a high-risk, high-reward funding strategy.
A survey of the CRISPR patent landscape shows the improvement of technology, a diversity of potential sectors of application, and a new geopolitical balance of forces in the field.
On the sixth anniversary of Mayo v. Prometheus, what impact has the US Supreme Court decision had on patent subject-matter eligibility and the prosecution of biotech-related patent applications before the US Patent and Trademark Office?
An analysis of published patent applications in chimeric antigen receptor (CAR) T-cell immunotherapy allows insight into the development of this emerging technology.
In the face of the Supreme Court’s double-novelty requirement and the negative impact that requirement has had on biotechnology, the time has come for a new paradigm of law.